Radius Health (NASDAQ:RDUS) on Wednesday said it had entered into new agreements for the expansion of its Tymlos injection to treat osteoporosis - a condition in which bones become weak and brittle - ...
Osteoporosis-related fractures are an important health concern because of related morbidity, mortality, and cost. 2 Bruce Mitlak, M.D., the Chief Medical Officer of Radius, emphasized that "30% of all ...
Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo. The Food and Drug Administration (FDA) has approved ...
"The real-world data presented further supports the favorable efficacy and safety profile of TYMLOS and why it is an important treatment option in the management of osteoporosis," said Dr. Felicia ...
Abaloparatide-Patch patient assessment study results demonstrated high patient acceptability and self-administration accuracy over a 29-day period Levels of PINP, a biomarker for bone formation, after ...
Radius Health, Inc. RDUS announced positive top-line data from the phase III ATOM study which is evaluating its lead product, Tymlos (abaloparatide 80 mg subcutaneous [“SC”]) injection, for use in men ...
Radius Reports Positive Phase 3 Results For TYMLOS Subcutaneous Injection In Males With Osteoporosis
(RTTNews) - Radius Health Inc. (RDUS) announced positive results from the ATOM Phase 3 Study evaluating TYMLOS or abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The company ...
BOSTON, MA / ACCESS Newswire / July 31, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. (“Radius” or the “Company”), a specialty biopharmaceutical company focused ...
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: In the past, I have been treated for osteoporosis, but still ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback